Related references
Note: Only part of the references are listed.Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe
Zhaoming Deng et al.
CANCER CELL INTERNATIONAL (2021)
Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
Zhichao Tian et al.
INVESTIGATIONAL NEW DRUGS (2020)
Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher
Petr Szturz et al.
ORAL ONCOLOGY (2020)
Anlotinib as a molecular targeted therapy for tumors
Yi Gao et al.
ONCOLOGY LETTERS (2020)
Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer
Maria A. Rodriguez-Hernandez et al.
REDOX BIOLOGY (2020)
Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway
Xiangrui Meng et al.
FRONTIERS IN ONCOLOGY (2020)
Apatinib, a Novel Tyrosine Kinase Inhibitor, Promotes ROS-Dependent Apoptosis and Autophagy via the Nrf2/HO-1 Pathway in Ovarian Cancer Cells
Xiaodan Sun et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2020)
Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade
Qian Yang et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma
Fei Song et al.
CELL DEATH & DISEASE (2020)
Transcriptome profiling analysis reveals that ATP6V0E2 is involved in the lysosomal activation by anlotinib
Xin Sun et al.
CELL DEATH & DISEASE (2020)
Reactive oxygen species mediate anlotinib-induced apoptosis via activation of endoplasmic reticulum stress in pancreatic cancer
Liguo Yang et al.
CELL DEATH & DISEASE (2020)
Head and Neck Cancer
Laura Q. M. Chow
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells
Jun Lu et al.
BMC MEDICAL GENOMICS (2019)
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Ai-Ping Zhou et al.
ONCOLOGIST (2019)
Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts
Arvind S. Mer et al.
CANCER RESEARCH (2019)
Sunitinib in the Treatment of Thyroid Cancer
Silvia Martina Ferrari et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
Y. Guo et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
Baohui Han et al.
BRITISH JOURNAL OF CANCER (2018)
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra et al.
BRITISH JOURNAL OF CANCER (2018)
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor
Chengying Xie et al.
CANCER SCIENCE (2018)
Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways
Laura Rosenberg et al.
CARCINOGENESIS (2018)
Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers
Lesley J. Scott
DRUGS (2018)
Molecular targeted therapy: Treating cancer with specificity
Yeuan Ting Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Anlotinib inhibits angiogenesis &ITvia&IT suppressing the activation of VEGFR2, PDGFRβ and FGFR1
Binyan Lin et al.
GENE (2018)
NADPH Oxidases and Mitochondria in Vascular Senescence
Gloria Salazar
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
NDRG2 contributes to cisplatin sensitivity through modulation of BAK-to-Mcl-1 ratio
Soojong Park et al.
CELL DEATH & DISEASE (2018)
Oxygen Consumption Rate Analysis of Mitochondrial Dysfunction Caused by Bacillus cereus Cereulide in Caco-2 and HepG2 Cells
Marlies Decleer et al.
TOXINS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial
Baohui Han et al.
JAMA ONCOLOGY (2018)
The role of cellular reactive oxygen species in cancer chemotherapy
Haotian Yang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Sorafenib: A Review in Hepatocellular Carcinoma
Gillian M. Keating
TARGETED ONCOLOGY (2017)
Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
Linda Tran et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Induction of reactive oxygen species: an emerging approach for cancer therapy
Zhengzhi Zou et al.
APOPTOSIS (2017)
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Yongkun Sun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy
Jean-Pascal Henry Machiels et al.
ONCOLOGIST (2016)
Reactive Oxygen Species Derived from NOX3 and NOX5 Drive Differentiation of Human Oligodendrocytes
Roberta Accetta et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
Cellular adaptation to nutrient deprivation: crosstalk between the mTORC1 and eIF2α signaling pathways and implications for autophagy
Jordan C. Wengrod et al.
CELL CYCLE (2015)
Phosphorylation of the translation initiation factor eIF2 alpha at serine 51 determines the cell fate decisions of Akt in response to oxidative stress
K. Rajesh et al.
CELL DEATH & DISEASE (2015)
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
T. Y. Seiwert et al.
ANNALS OF ONCOLOGY (2014)
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Manuel Hidalgo et al.
CANCER DISCOVERY (2014)
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
Jan B. Vermorken et al.
LANCET ONCOLOGY (2013)
Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie
M. Knoedler et al.
ONCOLOGY (2013)
Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors
B. J. M. Braakhuis et al.
ANNALS OF ONCOLOGY (2012)
Cross talk between mitochondria and NADPH oxidases
Sergey Dikalov
FREE RADICAL BIOLOGY AND MEDICINE (2011)
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
Jean-Pascal Machiels et al.
LANCET ONCOLOGY (2011)
The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
Peggy P. Hsu et al.
SCIENCE (2011)
Akt Determines Cell Fate Through Inhibition of the PERK-eIF2α Phosphorylation Pathway
Zineb Mounir et al.
SCIENCE SIGNALING (2011)
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment
J. Martinez-Trufero et al.
BRITISH JOURNAL OF CANCER (2010)
Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling Pathways
Fan Yang et al.
MOLECULAR CANCER RESEARCH (2010)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Endoplasmic reticulum stress exacerbates ischemia-reperfusion-induced apoptosis through attenuation of Akt protein synthesis in human choriocarcinoma cells
Hong-Wa Yung et al.
FASEB JOURNAL (2007)
Cetuximab - A review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer
Stephanie K. A. Blick et al.
DRUGS (2007)
The activation of Akt/PKB signaling pathway and cell survival
G Song et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2005)
Share Paper
